HLB PEP has registered the active pharmaceutical ingredient Vasopressin with the US FDA for use as an antidiuretic hormone. The registration action was announced on July 26, 2026. The API is intended for antidiuretic hormone therapy.
HLB PEP has registered Vasopressin API with the US Food and Drug Administration. This registration concerns the active pharmaceutical ingredient known as Vasopressin. The API is intended for use as an antidiuretic hormone. The registration was submitted by HLB PEP to the US FDA. The announcement of this registration took place on July 26, 2026.
The Vasopressin API registered by HLB PEP is an antidiuretic hormone. The registration was made with the US FDA. HLB PEP filed the registration for this specific API. The API is Vasopressin. The antidiuretic hormone is the intended therapeutic application. The US FDA is the regulatory agency that received the registration. The registration action was reported on July 26, 2026.
HLB PEP registered the Vasopressin API for an antidiuretic hormone. The filing was completed with the US FDA. The API registration covers Vasopressin. The antidiuretic hormone is the purpose of the registration. HLB PEP is the company that performed the registration. The announcement date is July 26, 2026. The US FDA registration is for the Vasopressin API as an antidiuretic hormone.
In summary, HLB PEP has registered Vasopressin API with the US FDA. The API is for antidiuretic hormone. The registration was announced on July 26, 2026. HLB PEP submitted the registration for Vasopressin API as an antidiuretic hormone to the US FDA. The active pharmaceutical ingredient is Vasopressin. The antidiuretic hormone is the intended use. The US FDA received the registration from HLB PEP.
Peptides referenced: Vasopressin.
Related reading: Semaglutide Benefits Persist Beyond First Year of Use, Study Shows, Compounded GLP-1 Drugs Raise Concerns for Doctors and FDA, FDA addresses peptide therapies as hype exceeds science, Sun Pharma Launches Generic Semaglutide in South Africa.